Literature DB >> 18629656

Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.

Abdulkader Obari1, Toshiaki Sano, Kenichi Ohyama, Eiji Kudo, Zhi Rong Qian, Akiko Yoneda, Nasim Rayhan, Muhammad Mustafizur Rahman, Shozo Yamada.   

Abstract

Pituitary adenomas producing almost exclusively growth hormones (GH) have been ultrastructurally classified into two distinct types: densely granulated somatotroph (DG) adenomas and sparsely granulated (SG) adenomas. Fibrous body (FB), an intracytoplasmic globular aggregation of cytokeratin (CK) filaments, is a hallmark of SG adenomas. Under light microscope, FB could be identified by CK immunohistochemistry as a dot-pattern immunoreaction versus a perinuclear pattern for cells without FB. However, it has been noted that numerous adenomas contain mixed populations of the two patterns. To clarify clinicopathological characteristics of the adenomas with mixed populations ("intermediate type" adenomas) and to confirm clinicopathological differences between strictly defined DG-type and SG-type adenomas, we performed this study on 104 GH cell adenomas. Having segregated "intermediate-type" adenomas (26 cases), we found significant differences between typical DG-type (47 cases) and SG-type adenomas (31 cases); SG-type adenomas had younger ages (44 vs. 50), higher frequency of macroadenomas (86% vs. 58%), invasiveness (65% vs. 38%), advanced grades (3 or 4) in Knosp's classification (50% vs. 24%), and weaker immunoreaction for GH, beta-TSH, alpha-subunit, E-cadherin, and beta-catenin. Clinicopathological characteristics of "intermediate-type" adenomas were identical to those of DG-type adenomas. These findings confirm that SG-type adenoma is a distinct section of GH cell adenomas with special properties and biological behavior, and suggest that intermediate-phenotype adenomas are enrolled in DG-type adenomas. Special properties and biological behavior of SG-type adenomas may appear after the majority of tumor cells possess a fully developed fibrous body.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629656     DOI: 10.1007/s12022-008-9029-z

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  17 in total

1.  Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments.

Authors:  P E Neumann; J E Goldman; D S Horoupian; M A Hess
Journal:  Arch Pathol Lab Med       Date:  1985-06       Impact factor: 5.534

2.  Morphogenesis and significance of fibrous bodies in human pituitary adenomas.

Authors:  E Horvath; K Kovacs
Journal:  Virchows Arch B Cell Pathol       Date:  1978-03-02

3.  Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children.

Authors:  J E Haas; N F Palmer; A G Weinberg; J B Beckwith
Journal:  Hum Pathol       Date:  1981-07       Impact factor: 3.466

4.  Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients.

Authors:  P R Mazal; T Czech; R Sedivy; M Aichholzer; J Wanschitz; N Klupp; H Budka
Journal:  Clin Neuropathol       Date:  2001 Jul-Aug       Impact factor: 1.368

5.  Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies.

Authors:  Bing Xu; Toshiaki Sano; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

6.  Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma.

Authors:  M P Scott; K F Helm
Journal:  Am J Dermatopathol       Date:  1999-02       Impact factor: 1.533

7.  Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary.

Authors:  S Yamada; T Sano; L Stefaneanu; K Kovacs; T Aiba; S Sawano; Y Shishiba
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

Review 8.  Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas.

Authors:  Toshiaki Sano; Qian Zhi Rong; Noriko Kagawa; Shozo Yamada
Journal:  Front Horm Res       Date:  2004       Impact factor: 2.606

9.  Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma.

Authors:  H Bando; T Sano; T Ohshima; C Y Zhang; R Yamasaki; K Matsumoto; S Saito
Journal:  Endocrinol Jpn       Date:  1992-08

10.  Cell type heterogeneity of intermediate filament expression in epithelia of the human pituitary gland.

Authors:  M Kasper; P Stosiek; G N van Muijen; R Moll
Journal:  Histochemistry       Date:  1989
View more
  56 in total

1.  Unusual type of growth hormone-producing pituitary tumor in acromegaly.

Authors:  Satoshi Yamagata; Kazunori Kageyama; Satoru Sakihara; Shozo Yamada; Shinobu Takayasu; Shinji Chikazawa; Naoko Inoshita; Toshiaki Sano; Toshihiro Suda
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

2.  MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2015-11-28       Impact factor: 3.633

3.  Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.

Authors:  Burak Kocak; Emine Sebnem Durmaz; Pinar Kadioglu; Ozge Polat Korkmaz; Nil Comunoglu; Necmettin Tanriover; Naci Kocer; Civan Islak; Osman Kizilkilic
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

4.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

5.  Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.

Authors:  Jian-Qiang Lu; Benjamin Adam; Andrew S Jack; Anna Lam; Robert W Broad; Constance L Chik
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

6.  Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Jens Bollerslev; Geir Ringstad
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

7.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

8.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

9.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

Review 10.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.